Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2)
Authors:
- Amir QaseemAQAmir Qaseem
- Jennifer YostJYJennifer Yost
- Itziar Etxeandia-IkobaltzetaIEItziar Etxeandia-Ikobaltzeta
- George M. AbrahamGAGeorge M. Abraham
- Janet A. JokelaJJJanet A. Jokela
- Mary Ann ForcieaMFMary Ann Forciea
- Matthew C. MillerMMMatthew C. Miller
- Timothy J. WiltTWTimothy J. Wilt
- Anjum S. KakaAKAnjum S. Kaka
- Roderick MacDonaldRMRoderick MacDonald
- Nancy GreerNGNancy Greer
- 1 May 2021
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 174 (5) , 673-679
Abstract
Clinicians must have access to the best available evidence to inform point-of-care decisions about the use of remdesivir in patients with COVID-19. This article provides updated advice from the Ame...Keywords
This publication has 5 references indexed in Scilit:
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19New England Journal of Medicine, 2020
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19JAMA, 2020
- A living WHO guideline on drugs for covid-19 (2020-2023)BMJ, 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020